CANF · Can-Fite BioPharma Ltd.

This Phase 2a trial represents a critical inflection point for namodenoson in pancreatic cancer — a high-unmet-need indication with historically poor outcomes and limited treatment options after first-line failure. The observation of stable disease in over 30% of evaluable patients, coupled with prolonged treatment duration in a substantial subset (35% still on therapy), provides early but meaningful evidence of biological and clinical activity. Notably, the study enrolled only heavily pretreated patients with advanced pancreatic adenocarcinoma who had progressed on at least one prior line or refused standard therapy — a population where durable stabilization is rare and clinically meaningful. The absence of new safety signals reinforces namodenoson’s established tolerability profile across oncology indications, reducing development risk. Management explicitly links the extended on-treatment duration to 'potential for durable clinical benefit', signaling confidence in the signal. With full efficacy analyses — including progression-free survival and overall survival — pending in the coming months and slated for presentation at an upcoming clinical conference, this data sets up a near-term value inflection. Importantly, the FDA Orphan Drug Designation already confers development incentives and market exclusivity potential, and success here could accelerate regulatory pathways or partnership discussions. While the trial remains small (20 evaluable patients) and uncontrolled, the consistency of the safety and durability signals strengthens the rationale for advancing into later-stage development, particularly given namodenoson’s ongoing Phase III trial in hepatocellular carcinoma and its mechanistic differentiation as a selective A3AR agonist.